Literature DB >> 19627527

Enamel matrix proteins; old molecules for new applications.

S P Lyngstadaas1, J C Wohlfahrt, S J Brookes, M L Paine, M L Snead, J E Reseland.   

Abstract

Emdogain (enamel matrix derivative, EMD) is well recognized in periodontology, where it is used as a local adjunct to periodontal surgery to stimulate regeneration of periodontal tissues lost to periodontal disease. The biological effect of EMD is through stimulation of local growth factor secretion and cytokine expression in the treated tissues, inducing a regenerative process that mimics odontogenesis. The major (>95%) component of EMD is Amelogenins (Amel). No other active components have so far been isolated from EMD, and several studies have shown that purified amelogenins can induce the same effect as the complete EMD. Amelogenins comprise a family of highly conserved extracellular matrix proteins derived from one gene. Amelogenin structure and function is evolutionary well conserved, suggesting a profound role in biomineralization and hard tissue formation. A special feature of amelogenins is that under physiological conditions the proteins self-assembles into nanospheres that constitute an extracellular matrix. In the body, this matrix is slowly digested by specific extracellular proteolytic enzymes (matrix metalloproteinase) in a controlled process, releasing bioactive peptides to the surrounding tissues for weeks after application. Based on clinical and experimental observations in periodontology indicating that amelogenins can have a significant positive influence on wound healing, bone formation and root resorption, several new applications for amelogenins have been suggested. New experiments now confirm that amelogenins have potential for being used also in the fields of endodontics, bone regeneration, implantology, traumatology, and wound care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19627527      PMCID: PMC2825346          DOI: 10.1111/j.1601-6343.2009.01459.x

Source DB:  PubMed          Journal:  Orthod Craniofac Res        ISSN: 1601-6335            Impact factor:   1.826


  47 in total

1.  The potential use of enamel matrix derivative for in situ anterior cruciate ligament tissue engineering: a translational in vitro investigation.

Authors:  Michael P Messenger; El Mustafa Raif; Bahaa B Seedhom; Steven J Brookes
Journal:  Tissue Eng       Date:  2007-08

2.  Amelogenin is a negative regulator of osteoclastogenesis via downregulation of RANKL, M-CSF and fibronectin expression in osteoblasts.

Authors:  Miyuki Nishiguchi; Kenji Yuasa; Kan Saito; Emiko Fukumoto; Aya Yamada; Tomokazu Hasegawa; Keigo Yoshizaki; Yoko Kamasaki; Kazuaki Nonaka; Taku Fujiwara; Satoshi Fukumoto
Journal:  Arch Oral Biol       Date:  2006-11-13       Impact factor: 2.633

3.  Anti-inflammatory properties of enamel matrix derivative in human blood.

Authors:  A E Myhre; S P Lyngstadaas; M K Dahle; J F Stuestøl; S J Foster; C Thiemermann; P Lilleaasen; J E Wang; A O Aasen
Journal:  J Periodontal Res       Date:  2006-06       Impact factor: 4.419

4.  The effects of LAMP1 and LAMP3 on M180 amelogenin uptake, localization and amelogenin mRNA induction by amelogenin protein.

Authors:  Liming Xu; Hidemitsu Harada; Akiyoshi Taniguchi
Journal:  J Biochem       Date:  2008-07-31       Impact factor: 3.387

5.  Effect of amelogenin extracellular matrix protein and compression on hard-to-heal venous leg ulcers: follow-up data.

Authors:  M Romanelli; E Kaha; H Stege; J W Wnorowski; P Vowden; H Majamaa; J L Lazaro
Journal:  J Wound Care       Date:  2008-01       Impact factor: 2.072

6.  Effect of amelogenin extracellular matrix protein and compression on hard-to-heal venous leg ulcers.

Authors:  P Vowden; M Romanelli; P Price
Journal:  J Wound Care       Date:  2007-05       Impact factor: 2.072

7.  Amelogenin binds to both heparan sulfate and bone morphogenetic protein 2 and pharmacologically suppresses the effect of noggin.

Authors:  Kan Saito; Ikuri Konishi; Miyuki Nishiguchi; Tomonori Hoshino; Taku Fujiwara
Journal:  Bone       Date:  2008-04-18       Impact factor: 4.398

8.  Identification of the functional activity of the [A-4] amelogenin gene splice product in newborn mouse ameloblasts.

Authors:  Stanca Iacob; Arthur Veis
Journal:  Bone       Date:  2008-02-15       Impact factor: 4.398

9.  Leucine-rich amelogenin peptide induces osteogenesis in mouse embryonic stem cells.

Authors:  Rungnapa Warotayanont; Danhong Zhu; Malcolm L Snead; Yan Zhou
Journal:  Biochem Biophys Res Commun       Date:  2007-12-18       Impact factor: 3.575

10.  Enamel matrix derivative induces connective tissue growth factor expression in human osteoblastic cells.

Authors:  Nora H M Heng; Philippe D N'Guessan; Bernd-Michael Kleber; Jean-Pierre Bernimoulin; Nicole Pischon
Journal:  J Periodontol       Date:  2007-12       Impact factor: 6.993

View more
  37 in total

1.  Gene array of primary human osteoblasts exposed to enamel matrix derivative in combination with a natural bone mineral.

Authors:  Richard J Miron; Dieter D Bosshardt; Yufeng Zhang; Daniel Buser; Anton Sculean
Journal:  Clin Oral Investig       Date:  2012-05-03       Impact factor: 3.573

2.  Effects of enamel matrix proteins in combination with a bovine-derived natural bone mineral for the repair of bone defects.

Authors:  Richard J Miron; Lingfei Wei; Dieter D Bosshardt; Daniel Buser; Anton Sculean; Yufeng Zhang
Journal:  Clin Oral Investig       Date:  2013-05-08       Impact factor: 3.573

3.  Bone grafting material in combination with Osteogain for bone repair: a rat histomorphometric study.

Authors:  Yufeng Zhang; Dai Jing; Daniel Buser; Anton Sculean; Fatiha Chandad; Richard J Miron
Journal:  Clin Oral Investig       Date:  2015-07-15       Impact factor: 3.573

4.  Biofunctionalization of porcine-derived collagen matrix using enamel matrix derivative and platelet-rich fibrin: influence on mature endothelial cell characteristics in vitro.

Authors:  Jung Soo Park; Andreas Max Pabst; Maximilian Ackermann; Maximilian Moergel; Junho Jung; Adrian Kasaj
Journal:  Clin Oral Investig       Date:  2017-07-11       Impact factor: 3.573

5.  Effects of enamel matrix derivative on non-surgical management of peri-implant mucositis: a double-blind randomized clinical trial.

Authors:  Atabak Kashefimehr; Reza Pourabbas; Masumeh Faramarzi; Ali Zarandi; Abouzar Moradi; Howard C Tenenbaum; Amir Azarpazhooh
Journal:  Clin Oral Investig       Date:  2016-12-30       Impact factor: 3.573

6.  Cloning and Expression Analysis of Human Amelogenin in Nicotiana benthamiana Plants by Means of a Transient Expression System.

Authors:  Mattia Pegoraro; Slavica Matić; Barbara Pergolizzi; Luca Iannarelli; Andrea M Rossi; Marco Morra; Emanuela Noris
Journal:  Mol Biotechnol       Date:  2017-10       Impact factor: 2.695

7.  Does enamel matrix derivative application improve clinical outcomes after semilunar flap surgery? A randomized clinical trial.

Authors:  Isabela Lima França-Grohmann; João Paulo Menck Sangiorgio; Manuela Rocha Bueno; Renato Corrêa Viana Casarin; Karina Gonzáles Silvério; Francisco Humberto Nociti; Márcio Zaffalon Casati; Enilson Antonio Sallum
Journal:  Clin Oral Investig       Date:  2018-06-12       Impact factor: 3.573

8.  Enamel matrix derivative promotes superoxide production and chemotaxis but reduces matrix metalloproteinase-8 expression by polymorphonuclear leukocytes.

Authors:  Mamdouh M Karima; Thomas E Van Dyke
Journal:  J Periodontol       Date:  2011-11-03       Impact factor: 6.993

9.  Application of induced pluripotent stem (iPS) cells in periodontal tissue regeneration.

Authors:  Xuejing Duan; Qisheng Tu; Jin Zhang; Jinhai Ye; Cesar Sommer; Gustavo Mostoslavsky; David Kaplan; Pishan Yang; Jake Chen
Journal:  J Cell Physiol       Date:  2011-01       Impact factor: 6.384

10.  Gene array of PDL cells exposed to Osteogain in combination with a bone grafting material.

Authors:  Richard J Miron; Yuang Shuang; Anton Sculean; Daniel Buser; Fatiha Chandad; Yufeng Zhang
Journal:  Clin Oral Investig       Date:  2016-01-08       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.